The primary endpoint was DFS, and secondary efficacy endpoints were OS in the intention to treat population (ITT) and DFS in the patients in the stage II–IIIA whose tumors expressed PD-L1 on 50% or more of the tumor cells. This evidence concerns the gene CD274 and neoplasm.